The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

To this day, multiple myeloma remains an incurable cancer. For many patients, recurrence is unavoidably a result of lacking treatment options in the minimal residual disease stage. This is due to residual and treatment-resistant myeloma cells that can cause disease relapse. However, patient-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Puttemans, Janik, Stijlemans, Benoit, Keyaerts, Marleen, Vander Meeren, Sam, Renmans, Wim, Fostier, Karel, Debie, Pieterjan, Hanssens, Heleen, Rodak, Magdalena, Pruszynski, Marek, De Veirman, Kim, Vanderkerken, Karin, Lahoutte, Tony, Morgenstern, Alfred, Bruchertseifer, Frank, Devoogdt, Nick, D'Huyvetter, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398099/
https://www.ncbi.nlm.nih.gov/pubmed/34667109
http://dx.doi.org/10.1158/1535-7163.MCT-21-0220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398099/
https://www.ncbi.nlm.nih.gov/pubmed/34667109
http://dx.doi.org/10.1158/1535-7163.MCT-21-0220

Ejemplares similares